$EVFM “Broad Street Alerts” Promoter Rank: 19/25 Evofem Biosciences, Inc. Newsletter 1:00:45 PM August 8, 2022

on August 8, 2022 Newsletters and Tags: , , , , , , , , , , with 0 comments

Overall Perfomance for "Broad Street Alerts"

The following three charts can be used by potential investors to gauge the performance of "Broad Street Alerts":


4 out of 11 campaigns closed down on first day


5 out of 11 campaigns closed up on first day


2 out of 11 campaigns had no net effect

EVFM Promotional Newsletter

The following is a newsletter released by "Broad Street Alerts" promoting Evofem Biosciences, Inc.


The following newsletter has not been verified for accuracy or completeness.

Reproductive Rights, Birth Control and Sexual Health are Hot Topics in America and Evofem EVFM is a Big Part of That Discussion

EVFM has a contraceptive that is hormone free, used on demand, and may be free to consumers.

Good day everyone,

Evofem Biosciences, Inc. NASDAQ EVFM has products to address unmet needs in women's sexual and reproductive health.

Current price $.84share as of 11AM EDT 8-8-22

We first talked about EVFM in early June when the company shares were priced at $.3466. Since then, EVFM shares have traded as high as $1.50share fueled by the SCOTUS decision to void abortion rights protection under the U.S. Constitution and leaving the establishment of those rights up to the individual states.

I want to talk about the company again because it still looks oversold, their Phexxi products sales are booming, and they have a steady stream of potential catalysts being reported. The company 10-Q for the second quarter ended June 30, 2022, hasnt been posted as of this report, but the company has provided a lot of financial data. Lets first look at why EVFM looks oversold

Cash $19.9M
Revenues Q2 $6.0M

QoQ revenue growth
Q321 $1.7M
Q421 $3.6M
Q122 $4.3M
Q222 $6.0M

Q2 2022 sales of Phexxi were up 42% over Q1 2022 and on Thursday, August 4th, the company reaffirmed guidance for $30-35M in FYE 2022 revenues representing a YoY increase of up to 335%.

622022 Laidlaw Initiated Coverage Buy $3.50
4122022 Morgan Stanley Underweight $7.95 $8.55

Potential catalysts since our initial report

The Evaluating Phexxi for the Prevention of Chlamydia and Gonorrhea in Women has just enrolled the last of 1,900 subjects in the study with topline data anticipated in October. Positive results from the study could be huge for the company making Phexxi an effective birth control products that also deters STDs.

Two weeks ago, the Departments of Labor, Health and Human Services, and Treasury released guidance clarifying that , including emergency contraceptives, at no cost to individuals.

In July, with a360 Media under which Phexxi branded content will appear in some of the most widely read entertainment and lifestyle magazines and websites in the U.S. a360 Media's Brands Include US Magazine, InTouch Weekly, and Woman's World.

The United States Patent and Trademark Office for patent application 16738,868 entitled, Compositions and Methods for Enhancing the Efficacy of Contraceptive Microbicides which covers the composition of matter of Phexxi lactic acid, citric acid, potassium bitartrate and is expected to provide protection into at least 2033.

I would be remiss if I didnt also point out this headline from a on July 21, featuring host Alexandra Semenova Short interests in Evofem jumps from 6% to 50% in June following the Roe v. Wade decision. Short interest in EVFM shares remains but as we all know, there is a price level that will squeeze those short sellers out.

Why Phexxi is a hot product and will continue to build market share

Hormone free Its a big deal as people around the world dont even want hormones in their food. There are a lot of effective birth control products already, pills, shots, implants IUDs and they are all hormone based. Phexxi is a combination of lactic acid, citric acid, and potassium bitartrate in a gel form. Hormone free

In an , EVFM CEO Saundra Pelletier said, Phexxi is the first and only birth control product that has no hormones, no systemic activity in the body, is the only birth control product that does not negatively impact a woman's ovaries and is used only when you need it and never when you don't.

According to Dr. Todd Chappell, a practicing obstetrician in an article published in the Journal of Therapeutic Advances in Reproductive Health, Phexxi offers women a truly innovative, on-demand and FDA-approved method to prevent pregnancy that does not alter the natural function of the ovaries.

Government guidelines that may make Phexxi free to most women recently issued July 29th. EVFM plans to renew discussions with insurers and pharmacy benefit managers PBMs that are not yet compliant with these guidelines to ensure they cover Phexxi lactic acid, citric acid, and potassium bitartrate at no cost to individuals.

According to Fortune Business Insights, the contraceptives market size was $22.49 billion in 2019 and is projected to reach $30.15 billion by 2028, exhibiting a CAGR of 5.5%. Given that projection, each 1% of the 2028 market will be worth $301M. So, the question to ponder is, how much market share could a product like Phexxi, a hormone free, effective contraceptive and potential STD inhibitor, achieve

EVFM shares are trading above their 50 SMA of $71. The 200 SMA of $4.59 seems, to me, to be more reflective of the true value of the company.

We will have more on EVFM soon,

The Team

Privacy Policy and Disclaimer

Your Consent

By using our site, you consent to our online privacy policy and disclaimer.

Do we disclose any information to outside parties

We do not sell, trade, or otherwise transfer to outside parties your personally identifiable information.

What information do we collect

We collect information from you when you subscribe to our newsletter or fill out a form on one of our social platforms. This includes your email address and or mobile phone number.

When registering on our site, as appropriate, you may be asked to enter your e-mail address and or mobile number.

What do we use your information for

When we collect your email or mobile number it is used for one purpose to send you the information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.

Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason whatsoever, other than for the express purpose of delivering the information on small cap stocks that you requested.

We send periodic emails

The email address you provide may be used to send you information, respond to inquiries, andor other requests or questions.

How do we protect your information

We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use secure third parties to send email and sms messages to you.

Because we value your privacy we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act.

Online Privacy Policy Only

This online privacy policy applies to information collected through our website and social media platforms.

Contacting Us

If there are any questions regarding this privacy policy or disclaimer you may reply to this email.


This websitenewsletter is a wholly owned subsidiary of Small Cap Specialists LLC, herein referred to as SCS LLC.

Our reportsreleases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our emailblog list as well as any social networking platforms we may use.
Remember, we choose who we work with. Our uncompensated reports are intended to help build our member base.

PLEASE NOTE WELL SCS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.

Release of Liability Through use of this website viewing or using you agree to hold SCS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss monetary or otherwise, damage monetary or otherwise, or injury monetary or otherwise that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. SCS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SCS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead SCS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. SCS LLC is compliant with the Can Spam Act of 2003. SCS LLC does not offer such advice or analysis, and SCS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.

The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions quote may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.

In preparing this publication, SCS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The owners and operators of this website have been compensated twenty two thousand five hundred dollars cash via bank wire by evofem biosiences inc for this weeks distributed opinions on evfm. The advertisements in this website are believed to be reliable, however, SCS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. SCS LLC is not responsible for any claims made by the companies advertised herein, nor is SCS LLC responsible for any other promotional firm, its program or its structure.
SCS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA.

Copyright 2022 Broad Street Alerts,